Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MB | P02144 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253572 | 1.00 | MB (0.37) | MBGSK3BNNMTAKR1B1AURKA | |
| SCHEMBL2849442 | 0.77 | MB (0.37) | MBGSK3BNNMTAKR1B1AURKA | |
| SCHEMBL2844929 | 0.77 | MB (0.37) | MBGSK3BNNMTAKR1B1AURKA | |
| SCHEMBL2844934 | 0.77 | MB (0.37) | MBGSK3BNNMTAKR1B1AURKA | |
| SCHEMBL1252548 | 0.74 | GSK3B (0.54) | GSK3B | |
| SCHEMBL1252551 | 0.74 | GSK3B (0.54) | GSK3B | |
| SCHEMBL15951381 | 0.73 | MB (0.66) | MBGSK3BAKR1B1AURKADAPK3 | |
| SCHEMBL1253776 | 0.73 | MB (0.41) | MBGSK3BNNMTAURKADAPK3 | |
| SCHEMBL20075991 | 0.71 | NNMT (0.56) | NNMTAKR1B1DYRK1A | |
| SCHEMBL2845174 | 0.70 | PNMT (0.44) | NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8450307-B2 | Therapeutic agents, and methods of making and using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | MB 367/4885GSK3B 4084/4885NNMT 619/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | MB 1817/4885GSK3B 2255/4885NNMT 3863/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | MB 367/4885GSK3B 4084/4885NNMT 619/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | MB 1817/4885GSK3B 2255/4885NNMT 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.